American Oncology Network Stock (OTC: AONCW)

Latest news for American Oncology Network (OTC:AONCW) Stock

American Oncology Network Inc is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. The company pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. It is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes.

American Oncology Network Inc Warrants (31/03/2028)

American Oncology Network Inc

EF Hutton analyst Jason Kolbert initiates coverage on Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) with a Buy rating and announces Price Target of $18.

News

Price Target

Initiation

Analyst Ratings

GOVX

EF Hutton Initiates Coverage On Geovax Labs with Buy Rating, Announces Price Target of $18

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) with a Neutral.

Reiteration

RAPT

HC Wainwright & Co. Reiterates Neutral on RAPT Therapeutics

Baird analyst Shrenik Kothari maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Outperform and lowers the price target from $350 to $335.

CRWD

Baird Maintains Outperform on CrowdStrike Holdings, Lowers Price Target to $335

Today, we&#39;re excited to share some changes that are coming - to our brand and the personalized experiences we&#39;re creating for our customers.
<ul>
<li>We recently rolled out a host of new features on the <a href="https://corporate.bestbuy.com/best-buy-unlocks-personalized-discovery-and-shopping-with-new-app/">Best Buy&reg; app</a> designed to give our customers a personalized shopping experience that&#39;s as unique as they are. This includes a new personalized home page, a Discover tab where customers can explore new tech, a Shop with Videos experience with personalized video content, personalized push notifications, a new Digital Wallet payment and rewards experience and much more. And just in time for the back-to-school season, we&#39;re helping customers find the right tech at the right price point. Customers can now choose to receive personalized alerts to make sure they don&#39;t miss when a product they&#39;ve had their eye on goes on sale, or when their exclusive member deals go live.</li>
</ul>
<ul>
<li>A growing number of our customers prefer video content when discovering and learning about technology. We&#39;re creating a new lineup of video content focused on innovators, new products, discovery, tech tips, buying guides, and more. More than 500 videos will be rolled out by the end of the year on the <a href="https://www.youtube.com/@BestBuy">Best Buy YouTube channel</a>, the Best Buy app and BestBuy.com. That&#39;s three times more than last year.</li>
</ul>
<ul>
<li>When our customers walk through our doors, we want them to get excited about all that can be discovered, and we&#39;ve reimagined how our stores can do just this. Later this summer and fall, we&#39;re introducing more experiential spaces in hundreds of stores that showcase the latest tech, from brands like GoPro, Tesla, Lovesac and Starlink.</li>
</ul>
<ul>
<li>In addition to their amazing expertise, our Blue Shirts and Geek Squad&reg; Agents are the ultimate champions of technology and helping our customers imagine what&#39;s possible. We&#39;re adding dedicated teams in our computing, appliance and home theater sections, which is exactly where our customers have told us they want support. We brought this to life during the recent launch of Copilot+ with <a href="https://corporate.bestbuy.com/best-buy-brings-copilot-pcs-to-life-for-customers/">more than 30,000 team members</a> ready to help.</li>
</ul>
<ul>
<li>We know that many of our customers like to do their own research. Our <a href="https://corporate.bestbuy.com/best-buy-cnet-partnership/">partnership with CNET</a> will allow us to integrate unbiased editorial advice from CNET&#39;s experts throughout every stage of the customer shopping journey across Best Buy channels - such as BestBuy.com, in store and on the Best Buy app.</li>
</ul>
<ul>
<li>This summer, through our new partnership with Google Cloud, we&#39;re providing our customers and employees with even more <a href="https://corporate.bestbuy.com/generative-ai-customer-support/">personalized, best-in-class tech support</a> experiences, including a gen AI-powered virtual assistant for customers who prefer a self-service option.</li>
</ul>

Tech

GOOG

GOOGL

Best Buy Announces Changes To Brand And Personalized Experiences For  Customers;  Announces Gen AI-powered Virtual Assistant In Partnership With Google Cloud For Customers Who Prefer Self-service Option

Baird analyst Joe Vruwink maintains Cadence Design Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) with a Outperform and lowers the price target from $341 to $338.

CDNS

Baird Maintains Outperform on Cadence Design Sys, Lowers Price Target to $338

In a recent development, Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) is making significant strides in the AI stock market, posing a challenge to Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
What Happened: The report, based on recent interactions with investors in New York and Connecticut, indicates that Broadcom&#8217;s specialized AI business is gaining traction, Business Insider<a href="https://markets.businessinsider.com/news/stocks/broadcom-vs-nvidia-ai-stock-investor-sentiment-citi-chips-avgo-2024-7"> reported</a> on Tuesday. The company has been assisting cloud giants like Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) and Amazon Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) in developing customized AI chips for internal use.
&#8220;AVGO is catching up to NVDA as the top holding as AVGO has more AI customers joining (OpenAI and Bytedance) and accretion from VMware,&#8221; Citi noted. However, Broadcom&#8217;s stock still lags behind Nvidia&#8217;s, with a 79% gain in a year compared to Nvidia&#8217;s 177%.
The shift in investor sentiment towards Broadcom is significant, given Nvidia&#8217;s dominance in the AI stock market. Other semiconductor companies, including NXP Semiconductors and Advanced Analog Devices, are also seeing increased investor interest due to expected inventory replenishments.
See Also: <a href="https://www.benzinga.com/news/24/07/39877477/microsoft-blames-european-commission-agreement-as-reason-it-cant-secure-windows-like-apple-secures-m?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Microsoft Blames European Commission Agreement As Reason It Can&#8217;t Secure Windows Like Apple Secures MacOS After CrowdStrike Outage</a>
Despite a mixed sentiment, Citi maintains a positive outlook on the semiconductor sector, stating, &#8220;We remain wildly bullish on semis.&#8221;
Why It Matters: Broadcom is targeting a massive artificial intelligence (AI)<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39793230/broadcom-has-over-150b-of-ai-silicon-opportunity-over-next-5-years-says-analyst"> silicon market opportunity</a>, worth over $150 billion in the next five years. This positions the tech giant for significant growth, both in the near term and long term.
Broadcom&#8217;s dominance in the $5-7 billion <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39354599/broadcoms-cutting-edge-ai-networking-technology-leaves-nvidia-marvell-cisco-behind-">data center/AI Ethernet switching</a> and routing chipset market, with a commanding 80% market share. This dominance is largely due to its relentless innovation.
Despite Broadcom&#8217;s progress, Nvidia could <a href="https://www.benzinga.com/markets/equities/24/07/39765205/nvidia-could-be-worth-nearly-50-trillion-in-a-decade-says-early-tesla-amazon-investor-nearly-2x-">achieve a market capitalization </a>of nearly $50 trillion within the next decade, according to tech investor James Anderson.
Price Action: On Tuesday, Broadcom was trading 0.11% lower in the pre-market after closing at $161.06 on Monday, according to <a href="https://pro.benzinga.com">Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39875506/crowdstrikes-faulty-microsoft-windows-update-gets-slammed-by-us-cybersecurity-official-was-a-huge-de?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Crowdstrike&#8217;s Faulty Microsoft Windows Update Gets Slammed By US Cybersecurity Official: &#8216;Was A Huge Deal&#8230;&#8217;</a></li>
</ul>
Image via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

General

AMZN

AVGO

NVDA

Broadcom To Challenge Nvidia Dominance? Analyst Says Jensen Huang-Led Chip Giant's Competitor Is 'Catching Up'

HC Wainwright &amp; Co. analyst Patrick Trucchio initiates coverage on Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) with a Buy rating and announces Price Target of $80.

BEAM

HC Wainwright & Co. Initiates Coverage On Beam Therapeutics with Buy Rating, Announces Price Target of $80

Wells Fargo analyst Roger Read initiates coverage on LandBridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LB#NYSE">LB</a>) with a Overweight rating and announces Price Target of $34.

Wells Fargo Initiates Coverage On LandBridge with Overweight Rating, Announces Price Target of $34

Directors Robert Langer and Stephen Berenson will also retire from the Board.

Management

MRNA

Carlyle Group Co-Founder And Co-Chairman David Rubenstein Joins Moderna's Board of Directors, Effective August 5, 2024 - Filing

Through a Memorandum of Understanding, Eve Air Mobility (&ldquo;Eve&rdquo;) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVEX#NYSE">EVEX</a>, EVEXW)), an aerospace manufacturer and service and solutions provider for electric vertical take-off and landing aircraft (eVTOLs), and Siemens Smart Infrastructure, a manufacturer of electrical and digital technologies and solutions, are teaming up to evaluate the electrical infrastructure and energy management services needed to support safe, efficient and scalable eVTOL operations. Together, the two companies will collaborate on evaluating the energy service needs for eVTOL aircraft and demand for these services across the United States as the Advanced Air Mobility (AAM) industry grows.

EVEX

Eve Air Mobility, Siemens Smart Infrastructure SIgn MoU To Evaluate Electrical Infrastructure And Energy Management For Scalable eVTOL Operations

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates Gold Royalty (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GROY#AMEX">GROY</a>) with a Buy and maintains $5.75 price target.

GROY

HC Wainwright & Co. Reiterates Buy on Gold Royalty, Maintains $5.75 Price Target

WIIM

CMCSA

Comcast shares are trading higher following Q2 earnings.

Baird analyst Eric Coldwell maintains IQVIA Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) with a Neutral and raises the price target from $235 to $251.

Baird Maintains Neutral on IQVIA Hldgs, Raises Price Target to $251

IRBT

iRobot Launches Roomba Combo 10 Max Robot + AutoWash Dock

Sherwin-Williams shares are trading higher after the company raised its 2024 guidance.

Voydeya&nbsp;(danicopan tablets) has been approved in Canada&nbsp;as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have residual hemolytic anemia due to extravascular hemolysis (EVH).1&nbsp;Voydeya&nbsp;is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care&nbsp;Ultomiris&nbsp;(ravulizumab) or&nbsp;Soliris&nbsp;(eculizumab) to address the needs of the approximately 10-20% of patients with PNH who experience clinically significant extravascular hemolysis (EVH) while treated with a C5 inhibitor.2,3

AstraZeneca Announced Voydeya Approved In Canada As Add-on Therapy To Ravulizumab Or Eculizumab For Adults With PNH Who Have Residual Hemolytic Anemia Due To Extravascular Hemolysis

Baird analyst David George maintains Zions Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) with a Neutral and raises the price target from $50 to $52.

ZION

Baird Maintains Neutral on Zions Bancorp, Raises Price Target to $52

BGNE

BeiGene Opens U.S. Biologics Manufacturing And Clinical R&D Facility In New Jersey With $800M Investment

The Company reiterated its full-year 2024&nbsp;outlook&nbsp;and updated its longer-term&nbsp;guidance&nbsp;on net leverage:
<ul>
<li>Total service revenue growth between&nbsp;4%&nbsp;and&nbsp;6%&nbsp;for full-year 2024. Total service revenue for 2023 was&nbsp;$584.5 million.</li>
<li>Full-year 2024 OEBITDA between&nbsp;$460 million&nbsp;and&nbsp;$470 million. OEBITDA for 2023 was&nbsp;$463.1 million.</li>
<li>Cash taxes of less than&nbsp;$10 million&nbsp;per year from 2024 through 2026. We expect that the longer-term cash tax rate will move closer to the statutory rate in 2028.</li>
<li>Net leverage below 4.0 times OEBITDA through 2026 and falling below 2.0 times OEBITDA by the end of the decade, assuming the completion of the Company&#39;s share repurchase authorization and the payment of quarterly dividends consistent with the current level. (Previous near-term&nbsp;guidance&nbsp;for net leverage was below 2.5 times OEBITDA as Iridium exited 2026.) Net leverage was 3.1 times OEBITDA at&nbsp;December 31, 2023.</li>
</ul>

Guidance

IRDM

Iridium Communications Reiterated FY24 Service Revenue Growth of 4%-6%, OEBITDA of $460M-$470M

Wells Fargo analyst Eric Luebchow upgrades Equinix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>) from Equal-Weight to Overweight and raises the price target from $825 to $875.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

American Oncology Network

News

Latest news for American Oncology Network (OTC:AONCW) Stock